Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Agenus inc. crawled time : 13:00 save search
SaponiQx and InvivoGen Announce Agreement for SaponiQx to Supply Cultured Plant Cell QS-21 Adjuvant
Published: 2024-04-17 (Crawled : 13:00) - biospace.com/
AGEN | $4.97 -7.96% -8.65% 1.7M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
qs-21 cell for agreement
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer
Published: 2024-04-12 (Crawled : 13:00) - biospace.com/
AGEN | $4.97 -7.96% -8.65% 1.7M
|
Health Technology
|
| O: 1842.45%
H: 0.0%
C: 0.0%
cancer
Agenus Reports Fourth Quarter and Full Year 2023 Results
Published: 2024-03-14 (Crawled : 13:00) - biospace.com/
AGEN | $4.97 -7.96% -8.65% 1.7M
|
Health Technology
|
| O: 1.73%
H: 0.0%
C: -10.49%
year results
Agenus Reports Second Quarter 2023 Results
Published: 2023-08-08 (Crawled : 13:00) - biospace.com/
AGEN | $4.97 -7.96% -8.65% 1.7M
|
Health Technology
|
| O: 0.74%
H: 0.72%
C: -8.76%
results
Agenus to Provide Second Quarter 2023 Financial Report and Corporate Update
Published: 2023-07-26 (Crawled : 13:00) - biospace.com/
AGEN | $4.97 -7.96% -8.65% 1.7M
|
Health Technology
|
| O: 0.66%
H: 1.22%
C: -1.32%
report update financial
GSK shares positive data for AREXVY, its respiratory syncytial virus (RSV) older adult vaccine, indicating protection over two RSV seasons
Published: 2023-06-21 (Crawled : 13:00) - biospace.com/
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: 0.55%
H: 1.09%
C: 0.98%
AGEN | $4.97 -7.96% -8.65% 1.7M
|
Health Technology
|
| O: 0.0%
H: 2.67%
C: -1.6%
respiratory positive rsv virus
Agenus Announces Virtual Annual Shareholders Meeting - June 5, 2023
Published: 2023-06-05 (Crawled : 13:00) - biospace.com/
AGEN | $4.97 -7.96% -8.65% 1.7M
|
Health Technology
|
| O: 0.63%
H: 11.18%
C: 7.45%
meeting
Agenus to Participate in February Investor Conferences
Published: 2023-01-26 (Crawled : 13:00) - globenewswire.com
AGEN | $4.97 -7.96% -8.65% 1.7M
|
Health Technology
|
| O: 0.81%
H: 0.4%
C: -2.01%
Agenus Presents Clinical Data Demonstrating Durable Responses of Botensilimab/Balstilimab Combination in Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI
Published: 2023-01-23 (Crawled : 13:00) - globenewswire.com
AGEN | $4.97 -7.96% -8.65% 1.7M
|
Health Technology
|
| O: 0.37%
H: 2.58%
C: -5.9%
asco cancer
Agenus to Provide Corporate Update and Third Quarter 2022 Financial Report
Published: 2022-10-25 (Crawled : 13:00) - globenewswire.com
AGEN | $4.97 -7.96% -8.65% 1.7M
|
Health Technology
|
| O: 0.76%
H: 5.32%
C: 0.0%
report financial update
GSK’s older adult RSV vaccine candidate, containing Agenus’ QS-21 STIMULON™, shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial
Published: 2022-10-13 (Crawled : 13:00) - globenewswire.com
AGEN | $4.97 -7.96% -8.65% 1.7M
|
Health Technology
|
| O: -3.15%
H: 6.1%
C: 4.88%
qs-21 disease vaccine trial
Agenus Initiates Botensilimab Phase 2 ACTIVATE Trials in Advanced MSS Colorectal Cancer and Advanced Melanoma
Published: 2022-09-12 (Crawled : 13:00) - globenewswire.com
AGEN | $4.97 -7.96% -8.65% 1.7M
|
Health Technology
|
| O: 0.37%
H: 0.37%
C: 0.0%
trials melanoma cancer phase 2
Agenus to Participate at BTIG Biotechnology Conference
Published: 2022-08-02 (Crawled : 13:00) - biospace.com/
AGEN | $4.97 -7.96% -8.65% 1.7M
|
Health Technology
|
| O: -0.8%
H: 4.88%
C: 4.47%
conference
Agenus Announces First Patient Dosed in Phase 1 Study of AGEN1571 (anti-ILT2) in Advanced Solid Tumors
Published: 2022-08-01 (Crawled : 13:00) - biospace.com/
AGEN | $4.97 -7.96% -8.65% 1.7M
|
Health Technology
|
| O: -1.16%
H: 2.75%
C: -2.75%
agen1571 study phase 1
Agenus to Provide Corporate Update and Second Quarter 2022 Financial ReportConference Call on Tuesday, August 9, 2022 at 8:30 a.m. ET
Published: 2022-07-27 (Crawled : 13:00) - biospace.com/
AGEN | $4.97 -7.96% -8.65% 1.7M
|
Health Technology
|
| O: 1.06%
H: 1.75%
C: 1.05%
update
Agenus to Participate at William Blair’s Biotech Focus Conference
Published: 2022-06-30 (Crawled : 13:00) - globenewswire.com
AGEN | $4.97 -7.96% -8.65% 1.7M
|
Health Technology
|
| O: -7.11%
H: 3.57%
C: -1.02%
conference biotech
Agenus to Host Investor Webcast to Review Late-Breaking Botensilimab and Balstilimab Data Presented at ESMO World GI Congress
Published: 2022-06-21 (Crawled : 13:00) - biospace.com/
AGEN | $4.97 -7.96% -8.65% 1.7M
|
Health Technology
|
| O: 12.41%
H: 0.0%
C: 0.0%
review
GSK’s RSV vaccine candidate for older adults, containing Agenus’ QS-21 STIMULON™ as part of GSK’s AS01 adjuvant, reports positive pivotal data supporting initiation of global regulatory submissions
Published: 2022-06-10 (Crawled : 13:00) - biospace.com/
AGEN | $4.97 -7.96% -8.65% 1.7M
|
Health Technology
|
| O: -6.51%
H: 0.0%
C: 0.0%
qs-21 vaccine positive order
Agenus to Provide Corporate Update and Third Quarter 2021 Financial Report
Published: 2021-10-25 (Crawled : 13:00) - globenewswire.com
AGEN | $4.97 -7.96% -8.65% 1.7M
|
Health Technology
|
| O: 3.31%
H: 0.37%
C: -6.65%
financial report
Agenus Provides Update on Balstilimab Development
Published: 2021-10-22 (Crawled : 13:00) - biospace.com/
AGEN | $4.97 -7.96% -8.65% 1.7M
|
Health Technology
|
| O: -23.39%
H: 0.0%
C: 0.0%
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.